NCT03660449View on ClinicalTrials.gov

Moderately Hypofractionated Conformal Radiation Combined With S-1 for Esophageal Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

July 30, 2022

Study Completion Date

July 30, 2022

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
COMBINATION_PRODUCT

Moderately hypofractionated conformal radiation combined With S-1

All patients will receive two cycles of S-1 (40mg/㎡, BID, po) on D1-14, D22-35, combined with thoracic radiotherapy of 60 Gy/24 fractions for GTV and 40 Gy/16 fractions for CTV.

Trial Locations (1)

510000

Hui Liu, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT03660449 - Moderately Hypofractionated Conformal Radiation Combined With S-1 for Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter